Last 12 months
Inside the activity.
1 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC |
Luptakova KatarinaCHIEF MEDICAL OFFICER
|
Exercise / conversionRestricted Stock Units · Derivative | 16,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000406 · form4-01032025_040113.xml · derivative · entry 2 Luptakova Katarina · CIK 0001991149 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,875 Underlying: Common Stock · 16,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC |
Luptakova KatarinaCHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 16,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000406 · form4-01032025_040113.xml · nonDerivative · entry 1 Luptakova Katarina · CIK 0001991149 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC |
Russo ReneDirector · PRESIDENT AND CEO
|
GrantStock Option (right to buy) · Derivative | 638,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000405 · form4-01032025_040111.xml · derivative · entry 3 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,000 Underlying: Common Stock · 638,000 shares Expires 2035-12-31 F3 · derivative.exercise_date: The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC |
Russo ReneDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 44,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000405 · form4-01032025_040111.xml · derivative · entry 2 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,750 Underlying: Common Stock · 44,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC |
Russo ReneDirector · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock | 44,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000405 · form4-01032025_040111.xml · nonDerivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC |
Frankenfield Christopher JamesChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 251,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000407 · form4-01032025_040116.xml · derivative · entry 4 Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251,000 Underlying: Common Stock · 251,000 shares Expires 2035-12-31 F4 · derivative.exercise_date: The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC |
Frankenfield Christopher JamesChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 19,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000407 · form4-01032025_040116.xml · derivative · entry 3 Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,125 Underlying: Common Stock · 19,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis F3 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F3 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC |
Frankenfield Christopher JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 19,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000407 · form4-01032025_040116.xml · nonDerivative · entry 1 Frankenfield Christopher James · CIK 0001988344 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000404 · form4-01032025_040109.xml · derivative · entry 4 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-12-31 F4 · derivative.exercise_date: The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000404 · form4-01032025_040109.xml · derivative · entry 3 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis F3 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F3 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:15 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000404 · form4-01032025_040109.xml · nonDerivative · entry 1 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:19 UTC |
GILEAD SCIENCES, INC.10% owner
|
PurchasePrefunded Warrants (right to buy) · Derivative | 6,092,816 | $1.04 Strike: $0.00 | $6,335,919.36 |
DisclosureSEC source: 0001062993-24-020910 · form4.xml · derivative · entry 2 GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,975,266 Underlying: Common Stock · 6,092,816 shares Expires not disclosed F1 · derivative.exercise_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer. F1 · derivative.expiration_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 21:19 UTC |
GILEAD SCIENCES, INC.10% owner
|
PurchaseCommon Stock | 1,759,978 | $1.04 | $1,830,377.12 |
DisclosureSEC source: 0001062993-24-020910 · form4.xml · nonDerivative · entry 1 GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,105,451 Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 21:15 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
GrantStock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001415889-24-024463 · form4-10022024_051001.xml · derivative · entry 1 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-09-30 F1 · derivative.exercise_date: The option was granted on October 1, 2024 and will vest as to 100% of the shares underlying the option on September 30, 2025, subject to the Reporting Person's continued service to the Issuer or its subsidiaries through the vesting date. Read SEC document |
| August 03, 2024 Filed Aug 7, 2024 00:00 UTC |
Frankenfield Christopher JamesChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001415889-24-020847 · form4-08062024_080802.xml · derivative · entry 1 Frankenfield Christopher James · CIK 0001988344 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2034-08-02 F1 · derivative.exercise_date: The option was granted on August 3, 2024 and will vest in equal monthly installments beginning on September 1, 2024 through August 1, 2028. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC |
Clancy Paul JDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017205 · form4-06172024_040604.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC |
Bonstein SaraDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017208 · form4-06172024_040613.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC |
ROSS ROBERT W.Director
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017207 · form4-06172024_040611.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC |
Rossi ChristinaDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017206 · form4-06172024_040607.xml · derivative · entry 1 Rossi Christina · CIK 0001756941 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC |
Xu YuanDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017210 · form4-06172024_040615.xml · derivative · entry 1 Xu Yuan · CIK 0001858214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:30 UTC |
Curran Daniel J.Director
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001415889-24-017204 · form4-06172024_040602.xml · derivative · entry 1 Curran Daniel J. · CIK 0001887599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option was granted on June 14, 2024 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 14, 2025 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 16:12 UTC |
Shannon James SamuelDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001415889-24-017160 · form4-06172024_080645.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option was granted on June 13, 2024 and will vest in three equal installments on June 13, 2025, June 13, 2026 and June 13, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:10 UTC |
Brennan AoifeDirector
|
GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001415889-24-017154 · form4-06172024_080637.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option was granted on June 13, 2024 and will vest in three equal installments on June 13, 2025, June 13, 2026 and June 13, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:10 UTC |
Luptakova KatarinaCHIEF MEDICAL OFFICER
|
GrantStock Option (right to buy) · Derivative | 59,333 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001415889-24-012151 · form4-05032024_040506.xml · derivative · entry 1 Luptakova Katarina · CIK 0001991149 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,333 Underlying: Common Stock · 59,333 shares Expires 2034-04-30 F1 · derivative.exercise_date: The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:10 UTC |
Russo ReneDirector · PRESIDENT AND CEO
|
GrantStock Option (right to buy) · Derivative | 474,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001415889-24-012149 · form4-05032024_040501.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,000 Underlying: Common Stock · 474,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:10 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001415889-24-012152 · form4-05032024_040509.xml · derivative · entry 1 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:10 UTC |
Frankenfield Christopher JamesCHIEF OPERATING OFFICER
|
GrantStock Option (right to buy) · Derivative | 208,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001415889-24-012150 · form4-05032024_040504.xml · derivative · entry 1 Frankenfield Christopher James · CIK 0001988344 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,000 Underlying: Common Stock · 208,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 22:50 UTC |
GILEAD SCIENCES, INC.10% owner
|
PurchasePrefunded Warrants (right to buy) · Derivative | 3,882,450 | $0.76 Strike: $0.00 | $2,950,273.76 |
DisclosureSEC source: 0001062993-24-008004 · form4.xml · derivative · entry 2 GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,882,450 Underlying: Common Stock · 3,882,450 shares Expires not disclosed F1 · derivative.exercise_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer. F1 · derivative.expiration_date: The Prefunded Warrants have no expiration date and are exercisable at any time on or after the date of issuance. A holder of Prefunded Warrants may not exercise the Prefunded Warrants if, after giving effect to such exercise, the holder and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the outstanding shares of Common Stock of the Issuer. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 22:50 UTC |
GILEAD SCIENCES, INC.10% owner
|
PurchaseCommon Stock | 485,250 | $0.76 | $368,790.00 |
DisclosureSEC source: 0001062993-24-008004 · form4.xml · nonDerivative · entry 1 GILEAD SCIENCES, INC. · CIK 0000882095 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,345,473 Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:33 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 267 | $0.64 | $170.88 |
DisclosureSEC source: 0001209191-24-003031 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 734,546 F2 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:33 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 733 | $0.64 | $469.12 |
DisclosureSEC source: 0001209191-24-003031 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,019,563 F1 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 23:16 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 560 | $0.83 | $464.80 |
DisclosureSEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 4 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 734,813 F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 23:16 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 1,540 | $0.83 | $1,278.20 |
DisclosureSEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 3 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,020,296 F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:16 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 569 | $0.87 | $495.03 |
DisclosureSEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 2 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 735,373 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.9499 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:16 UTC |
Atlas Venture Fund XI, L.P.10% owner
Atlas Venture Associates XI, L.P.10% owner
Atlas Venture Associates XI, LLC10% owner
|
SaleCommon Stock | 1,566 | $0.87 | $1,362.42 |
DisclosureSEC source: 0001209191-24-001655 · doc4.xml · nonDerivative · entry 1 Atlas Venture Fund XI, L.P. · CIK 0001708269 · 10% owner Atlas Venture Associates XI, L.P. · CIK 0001780068 · 10% owner Atlas Venture Associates XI, LLC · CIK 0001780067 · 10% owner Atlas Venture Opportunity Fund I, L.P. · CIK 0001759241 · 10% owner Atlas Venture Associates Opportunity I, L.P. · CIK 0001780065 · 10% owner Atlas Venture Associates Opportunity I, LLC · CIK 0001780066 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,021,836 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.9499 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:15 UTC |
Luptakova KatarinaCHIEF MEDICAL OFFICER
|
GrantRestricted Stock Units · Derivative | 66,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000278 · form4-01032024_040105.xml · derivative · entry 1 Luptakova Katarina · CIK 0001991149 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,500 Underlying: Common Stock · 66,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:15 UTC |
Russo ReneDirector · PRESIDENT AND CEO
|
GrantRestricted Stock Units · Derivative | 177,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000276 · form4-01032024_040101.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:38 UTC |
Frankenfield Christopher JamesCHIEF OPERATING OFFICER
|
GrantRestricted Stock Units · Derivative | 77,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000305 · form4-01032024_090105.xml · derivative · entry 1 Frankenfield Christopher James · CIK 0001988344 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:15 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000277 · form4-01032024_040103.xml · derivative · entry 1 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 16:26 UTC |
Luptakova KatarinaChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 106,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001104659-23-098959 · tm2325621-2_4seq1.xml · derivative · entry 1 Luptakova Katarina · CIK 0001991149 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,000 Underlying: Common Stock · 106,000 shares Expires 2033-09-04 F1 · derivative.exercise_date: The option was granted on September 5, 2023 and will vest in equal monthly installments beginning on October 1, 2023 through September 1, 2027. Read SEC document |
| August 16, 2023 Filed Aug 19, 2023 00:30 UTC |
Huber Martin H. Jr.PRESIDENT AND HEAD OF R&D
|
GrantStock Option (right to buy) · Derivative | 136,500 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-23-012415 · form4-08182023_080801.xml · derivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · PRESIDENT AND HEAD OF R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,500 Underlying: Common Stock · 136,500 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:45 UTC |
Russo ReneDirector · CEO
|
GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-23-012418 · form4-08182023_080801.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. Read SEC document |
| August 16, 2023 Filed Aug 19, 2023 00:40 UTC |
Frankenfield Christopher JamesCHIEF OPERATING OFFICER
|
GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-23-012417 · form4-08182023_080801.xml · derivative · entry 1 Frankenfield Christopher James · CIK 0001988344 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. Read SEC document |
| August 16, 2023 Filed Aug 19, 2023 00:35 UTC |
Brennan Kevin M.SVP, FINANCE AND ACCOUNTING
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-23-012416 · form4-08182023_080801.xml · derivative · entry 1 Brennan Kevin M. · CIK 0001971303 · SVP, FINANCE AND ACCOUNTING 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:12 UTC |
Frankenfield Christopher JamesChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001104659-23-088350 · tm2323038-2_4seq1.xml · derivative · entry 1 Frankenfield Christopher James · CIK 0001988344 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-08-02 F1 · derivative.exercise_date: The option was granted on August 3, 2023 and will vest in equal monthly installments beginning on September 1, 2023 through August 1, 2027. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC |
Clancy Paul JDirector
|
GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009738 · form4-06132023_040612.xml · derivative · entry 1 Clancy Paul J · CIK 0001409601 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC |
Bonstein SaraDirector
|
GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009739 · form4-06132023_040615.xml · derivative · entry 1 Bonstein Sara · CIK 0001604019 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC |
ROSS ROBERT W.Director
|
GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009741 · form4-06132023_040623.xml · derivative · entry 1 ROSS ROBERT W. · CIK 0001733077 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC |
Rossi ChristinaDirector
|
GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009737 · form4-06132023_040610.xml · derivative · entry 1 Rossi Christina · CIK 0001756941 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:30 UTC |
Heyman Tomas J.Director
|
GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001415889-23-009740 · form4-06132023_040620.xml · derivative · entry 1 Heyman Tomas J. · CIK 0001814673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2023 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 12, 2024 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.